Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Closes Acquisition of PersonalizeDx

NEW YORK (GenomeWeb) – Rosetta Genomics today announced that it has completed its previously announced acquisition of CynoGen, a molecular diagnostics firm doing business as PersonalizeDx.

Rosetta bought the firm from Prelude Corp., which recently acquired CynoGen from Abbott, in exchange for $2 million, 500,000 of Rosetta's ordinary shares, and certain undisclosed assets and services.

Through the deal, Rosetta has picked up PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab in Lake Forest, Calif. Also included in the deal is Prelude's assay for ductal carcinoma in situ, a prognostic test designed to differentiate stage 0 breast cancer patients at high and low risk for disease recurrence, as well those likely to respond to therapy versus those who are not.

Rosetta said that PersonalizeDx recorded 2014 revenues of $6.9 million. Following the acquisition, Rosetta anticipates its 2015 revenues will be in the range of $10 million to $12 million, and its 2016 revenues will exceed $18 million.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.